Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MOLN
MOLN logo

MOLN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Molecular Partners AG (MOLN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.930
1 Day change
1.55%
52 Week Range
5.360
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Molecular Partners AG (MOLN) is not a good buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has bearish technical indicators, no significant trading trends, and no recent catalysts to drive growth. Additionally, there are no proprietary trading signals or financial performance data to support a buy decision.

Technical Analysis

The MACD is slightly positive but contracting, indicating weakening momentum. The RSI is neutral at 43.511, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.892, with resistance at 4.06 and support at 3.724. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

  • NULL identified. There is no recent news, no significant insider or hedge fund activity, and no congress trading data.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of trading trends, and a projected negative price trend (-1.43% in the next day, -2.88% in the next week, -2.36% in the next month).

Financial Performance

No financial performance data available due to an error in the data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast MOLN stock price to rise
2 Analyst Rating
Wall Street analysts forecast MOLN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.870
sliders
Low
8
Averages
10
High
12
Current: 3.870
sliders
Low
8
Averages
10
High
12
H.C. Wainwright
Buy
initiated
$13
AI Analysis
2026-01-27
Reason
H.C. Wainwright
Price Target
$13
AI Analysis
2026-01-27
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Molecular Partners with a Buy rating and $13 price target. The company is advancing a "diversified portfolio of agents" centered on the DARPin platform, the analyst tells investors in a research note. The firm says Molecular Partners is focused on targeted radiotherapy agents to address areas of serious unmet needs within oncology.
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-12-08
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-12-08
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $3.75 from $4 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MOLN
Unlock Now

People Also Watch